12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Labetuzumab-SN-38: Interim Phase I data

Interim data from 11 patients with metastatic colorectal cancer in an open-label, dose-escalation, U.S. Phase I trial showed that 2, 4, 8 and 16 mg/kg doses of labetuzumab-SN-38 every 2 weeks were generally well tolerated. A dose-limiting toxicity (DLT) of grade 3 thrombocytopenia occurred at the...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >